Top

Published in:

01-10-2009 | Original Article

Association of Allogeneic Blood Transfusions and Long-Term Survival of Patients with Gastric Cancer after Curative Gastrectomy

Authors: Toshiyasu Ojima, Makoto Iwahashi, Mikihito Nakamori, Masaki Nakamura, Teiji Naka, Masahiro Katsuda, Takeshi Iida, Keiji Hayata, Hiroki Yamaue

Published in: Journal of Gastrointestinal Surgery | Issue 10/2009

Abstract

Introduction

The relationship between perioperative allogeneic blood transfusions and poor prognosis in patients with gastric cancer remains controversial. The aim of this study is to examine the effect of perioperative blood transfusions on long-term survival of patients undergoing curative gastric resection for gastric cancer.

Methods

Eight hundred fifty-six consecutive patients with gastric cancer who underwent curative gastrectomy (R0) from January 1, 1991 through December 31, 2002 were enrolled in this retrospective study.

Results

A multivariate overall survival analysis using Cox proportional hazard regression model revealed macroscopically infiltrative tumor, tumor infiltration of serosa, lymph node metastasis, blood transfusions (hazard ratio, 2.69), pulmonary disease, and liver dysfunction as prognostic factors for long-term survival. Blood transfusion was an independent prognostic factor at all stages of disease. Disease-specific and overall survival showed significant differences between the transfused and nontransfused groups (log-rank, P < 0.0001). Based on multivariate logistic regression analysis, the need for blood transfusion was significantly associated with advanced age (≥65 years), long duration of operation (≥300 min), massive blood loss (≥1,000 ml), and anemia (Hb < 10 g/dl).

Conclusions

Allogeneic blood transfusion is an independent prognostic factor for long-term survival in gastric cancer patients.

Yamamoto J, Kosuge T, Takayama T et al. Perioperative blood transfusion promotes recurrence of hepatocellular carcinoma after hepatectomy. Surgery 1994;115:303–309.PubMed

Hyman NH, Foster RS Jr, DeMeules JE, Costanza MC. Blood transfusions and survival after lung cancer resection. Am J Surg 1985;149:502–507.PubMedCrossRef

Tartter PI, Burrows L, Papatestas AE, Lesnick G, Aufses AH Jr. Perioperative blood transfusion has prognostic significance for breast cancer. Surgery 1985;97:225–230.PubMed

Jones KR, Weissler MC. Blood transfusion and other risk factors for recurrence of cancer of the head and neck. Arch Otolaryngol Head Neck Surg 1990;116:304–309.PubMed

Foster RS Jr, Costanza MC, Foster JC, Wanner MC, Foster CB. Adverse relationship between blood transfusions and survival after colectomy for colon cancer. Cancer 1985;55:1195–1201.PubMedCrossRef

Heal JM, Chuang C, Blumberg N. Perioperative blood transfusions and prostate cancer recurrence and survival. Am J Surg 1988;156:374–380.PubMedCrossRef

Wu HS, Little AG. Perioperative blood transfusions and cancer recurrence. J Clin Oncol 1988;6:1348–1354.PubMed

Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 2003;14(suppl 2):ii31–36.PubMed

Sasako M, Sano T, Yamamoto S et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008;359:453–462.PubMedCrossRef

10.

Kampschöer GH, Maruyama K, Sasako M, Kinoshita T, van de Velde CJ. The effects of blood transfusion on the prognosis of patients with gastric cancer. World J Surg 1989;13:637–643.PubMedCrossRef

11.

Moriguchi S, Maehara Y, Akazawa K, Sugimachi K, Nose Y. Lack of relationship between perioperative blood transfusion and survival time after curative resection for gastric cancer. Cancer 1990;66:2331–2335.PubMedCrossRef

12.

Choi JH, Chung HC, Yoo NC et al. Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gastric cancer. Oncology 1995;52:170–175.PubMedCrossRef

13.

Bortul M, Calligaris L, Roseano M, Leggeri A. Blood transfusions and results after curative resection for gastric cancer. Suppl Tumori 2003;2:S27–30.PubMed

14.

Sánchez-Bueno F, García-Marcilla JA, Pérez-Abad JM, Vicente R, Aranda F, Lujan JA, Parrilla P. Does perioperative blood transfusion influence long-term prognosis of gastric cancer. Dig Dis Sci 1997;42:2072–2076.PubMedCrossRef

15.

Dhar DK, Kubota H, Tachibana M et al. A tailored perioperative blood transfusion might avoid undue recurrences in gastric carcinoma patients. Dig Dis Sci 2000;45:1737–1742.PubMedCrossRef

16.

Hyung WJ, Noh SH, Shin DW, Huh J, Huh BJ, Choi SH, Min JS. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002;9:5–12.PubMedCrossRef

17.

Kaneda M, Horimi T, Ninomiya M et al. Adverse affect of blood transfusions on survival of patients with gastric cancer. Transfusion 1987;27:375–377.PubMedCrossRef

18.

Fong Y, Karpeh M, Mayer K, Brennan MF. Association of perioperative transfusions with poor outcome in resection of gastric adenocarcinoma. Am J Surg 1994;167:256–260.PubMedCrossRef

19.

Maeta M, Shimizu N, Oka A et al. Perioperative allogeneic blood transfusion exacerbates surgical stress-induced postoperative immunosuppression and has a negative effect on prognosis in patients with gastric cancer. J Surg Oncol 1994;55:149–153.PubMedCrossRef

20.

Sobin LH, Wittekind CH. International Union Against Cancer (UICC): TNM Classification of Malignant Tumors. 5th ed. New York: Wiley, 1997.

21.

Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107–1136.

22.

Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285–1295.PubMedCrossRef

23.

Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child–Pugh versus MELD. J Hepatol 2005;42:100–107.CrossRef

24.

Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539–553.PubMedCrossRef

25.

Erslev AJ. Erythropoietin and anemia of cancer. Eur J Haematol 2000;64:353–358.PubMedCrossRef

26.

Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. 13th ed. Tokyo: Kanehara, 1999.

27.

Jauch KW, Heiss MM, Gruetzner U et al. Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol 1996;14:1810–1817.PubMed

28.

Heiss MM, Simon EH, Beyer BC et al. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow. J Clin Oncol 2002;20:2005–2016.PubMedCrossRef

29.

Heiss MM, Allgayer H, Gruetzner KU et al. Prognostic influence of blood transfusion on minimal residual disease in resected gastric cancer patients. Anticancer Res 1997;17:2657–2661.PubMed

30.

Kooby DA, Stockman J, Ben-Porat L et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003;237:860–869.PubMedCrossRef

31.

Sun CF, Hsieh YY, Ngan KW, Wang WT. Search for immunomodulatory effects of blood transfusion in gastric cancer patients: flow cytometry of Th1/Th2 cells in peripheral blood. Ann Clin Lab Sci 2001;31:171–178.PubMed

32.

Baumgartner JM, Silliman CC, Moore EE, Banerjee A, McCarter MD. Stored red blood cell transfusion induces regulatory T cells. J Am Coll Surg 2009;208:110–119.PubMedCrossRef

33.

Zhang H, Chua KS, Guimond M et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005;11:1238–1243.PubMedCrossRef

34.

Chen G, Zhang FJ, Gong M, Yan M. Effect of perioperative autologous versus allogeneic blood transfusion on the immune system in gastric cancer patients. J Zhejiang Univ Sci B 2007;8:560–565.PubMedCrossRef

35.

Ojima T, Iwahashi M, Nakamori M et al. Influence of overweight on patients with gastric cancer after undergoing curative gastrectomy: an analysis of 689 consecutive cases managed by a single center. Arch Surg 2009;144:351–358.PubMedCrossRef

36.

Wagman LD. “Necessary” transfusions and prognosis in gastric cancer. Ann Surg Oncol 2002;9:1–2.PubMedCrossRef

37.

Memon MA, Khan S, Yunus RM, Barr R, Memon B. Meta-analysis of laparoscopic and open distal gastrectomy for gastric carcinoma. Surg Endosc 2008;22:1781–1789.PubMedCrossRef

38.

Busch OR, Hop WC, Hoynck van Papendrecht MA, Marquet RL, Jeekel J. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372–1376.PubMedCrossRef

39.

Winslow RM. New transfusion strategies: red cell substitutes. Annu Rev Med 1999;50:337–353.PubMedCrossRef

40.

Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. Br Med Bull 1999;55:277–298.PubMedCrossRef

Title: Association of Allogeneic Blood Transfusions and Long-Term Survival of Patients with Gastric Cancer after Curative Gastrectomy
Authors: Toshiyasu Ojima
Makoto Iwahashi
Mikihito Nakamori
Masaki Nakamura
Teiji Naka
Masahiro Katsuda
Takeshi Iida
Keiji Hayata
Hiroki Yamaue
Publication date: 01-10-2009
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue 10/2009
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-009-0973-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Association of Allogeneic Blood Transfusions and Long-Term Survival of Patients with Gastric Cancer after Curative Gastrectomy

Abstract

Introduction

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2009

Laparoscopic Duodenojejunostomy for Superior Mesenteric Artery Syndrome—How I Do It

Very High Serum CA 19-9 Levels: A Contraindication to Pancreaticoduodenectomy?

National Complication Rates after Pancreatectomy: Beyond Mere Mortality

Outcome after Resection of Hepatic and Pulmonary Metastases of Colorectal Cancer

“Above Average” SSAT Presidential Address 2009

Effective Treatment of Advanced Colorectal Cancer by Rapamycin and 5-FU/Oxaliplatin Monitored by TIMP-1